# NAGA

## Overview
The NAGA gene encodes the enzyme alpha-N-acetylgalactosaminidase, a lysosomal hydrolase involved in the degradation of glycoproteins and glycolipids. This enzyme is crucial for hydrolyzing terminal alpha-N-acetylgalactosaminyl residues from various substrates, thereby playing a significant role in cellular metabolism and homeostasis (Wang1990Human). The NAGA gene is located on chromosome 22q13 and shares structural similarities with the alpha-galactosidase A gene, indicating an evolutionary relationship (Wang1991Structural). Mutations in the NAGA gene can lead to lysosomal storage disorders such as Schindler disease and Kanzaki disease, characterized by the accumulation of undegraded substrates due to deficient enzyme activity (Clark2009The). The enzyme's structure, featuring a (β/α)8-barrel and a β-sandwich fold, is essential for its catalytic function and stability, with specific mutations causing significant structural disruptions and clinical manifestations (Sakuraba2003Structural).

## Structure
The human α-N-acetylgalactosaminidase (NAGA) protein is a lysosomal enzyme encoded by the NAGA gene located on chromosome 22q13. The protein consists of 387 amino acids, excluding the N-terminal signal peptide and C-terminal residues not determined in the chicken structure used for modeling (Sakuraba2003Structural). The primary structure of NAGA is characterized by a sequence that shares significant homology with the α-galactosidase A gene, suggesting an evolutionary relationship (Wang1991Structural).

The secondary structure of NAGA includes two distinct domains. Domain I, comprising residues 18-311, forms a (β/α)8-barrel that contains the active site. Domain II, spanning residues 312-404, features a β-sandwich fold (Sakuraba2003Structural). These structural elements are crucial for the enzyme's catalytic function and stability.

Mutations such as R329W and R329Q disrupt hydrogen bonding between domains I and II, leading to significant structural changes and potential loss of function (Sakuraba2003Structural). The protein's tertiary structure is stabilized by these inter-domain interactions, which are essential for maintaining its functional conformation.

Post-translational modifications, such as glycosylation, are common in lysosomal enzymes like NAGA, although specific modifications for NAGA are not detailed in the provided context.

## Function
The NAGA gene encodes the enzyme alpha-N-acetylgalactosaminidase, which plays a crucial role in the lysosomal degradation of glycoproteins and glycolipids. This enzyme is responsible for hydrolyzing terminal alpha-N-acetylgalactosaminyl residues from various substrates, including glycopeptides, glycoproteins, glycosphingolipids, and proteoglycans (Wang1990Human). The enzyme is synthesized as a 65-kDa glycosylated precursor and is processed into a mature 48-kDa lysosomal form. The precursor form contains high mannose type oligosaccharide chains, with mannose residues being phosphorylated only in the precursor (Wang1990Human).

In healthy human cells, alpha-N-acetylgalactosaminidase is active within the lysosome, an organelle responsible for breaking down waste materials and cellular debris. The enzyme's activity is essential for maintaining cellular homeostasis by preventing the accumulation of undegraded substrates, which can lead to metabolic disorders (Keulemans1996Human). Proper function of this enzyme ensures the efficient recycling of biomolecules, contributing to overall cellular metabolism and health (Keulemans1996Human). The NAGA gene's role in these processes highlights its importance in cellular and organismal biology.

## Clinical Significance
Mutations in the NAGA gene, which encodes the enzyme α-N-acetylgalactosaminidase, lead to lysosomal storage disorders such as Schindler disease and Kanzaki disease. Schindler disease is categorized into three types: Type I is a severe infantile neurodegenerative disorder, Type II (Kanzaki disease) presents with mild cognitive impairments and skin lesions, and Type III includes symptoms like seizures and cardiomyopathy (Clark2009The). These conditions result from the accumulation of glycopeptides and glycolipids due to deficient enzyme activity (Clark2009The).

Specific mutations in the NAGA gene, such as D217N, E325K, and R329W, disrupt the enzyme's structure and function, leading to varying clinical manifestations. The E325K mutation is associated with severe phenotypes in some cases but not in others, highlighting the clinical heterogeneity of the disease (Keulemans1996Human; Sakuraba2003Structural). The R329W mutation, in particular, causes significant structural changes, resulting in more severe symptoms compared to the R329Q mutation (Kanekura2005Three).

The genotype-phenotype correlation in NAGA-related disorders is complex, with some mutations leading to severe symptoms while others result in milder forms of the disease (Bakker2001Human; Keulemans1996Human). This suggests that other genetic or environmental factors may influence the clinical presentation of these disorders (Sakuraba2003Structural).


## References


[1. (Wang1990Human) A M Wang, D F Bishop, and R J Desnick. Human alpha-n-acetylgalactosaminidase-molecular cloning, nucleotide sequence, and expression of a full-length cdna. homology with human alpha-galactosidase a suggests evolution from a common ancestral gene. Journal of Biological Chemistry, 265(35):21859–21866, December 1990. URL: http://dx.doi.org/10.1016/s0021-9258(18)45818-8, doi:10.1016/s0021-9258(18)45818-8. This article has 53 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)45818-8)

[2. (Sakuraba2003Structural) Hitoshi Sakuraba, Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Masaharu Kotani, Hiroshi Nakada, Tomoko Fukushige, and Tamotsu Kanzaki. Structural and immunocytochemical studies on α-n-acetylgalactosaminidase deficiency (schindler/kanzaki disease). Journal of Human Genetics, 49(1):1–8, December 2003. URL: http://dx.doi.org/10.1007/s10038-003-0098-z, doi:10.1007/s10038-003-0098-z. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10038-003-0098-z)

[3. (Wang1991Structural) Anne M. Wang and Robert J. Desnick. Structural organization and complete sequence of the human α-n-acetylgalactosaminidase gene: homology with the α-galactosidase a gene provides evidence for evolution from a common ancestral gene. Genomics, 10(1):133–142, May 1991. URL: http://dx.doi.org/10.1016/0888-7543(91)90493-x, doi:10.1016/0888-7543(91)90493-x. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0888-7543(91)90493-x)

[4. (Keulemans1996Human) J L Keulemans, A J Reuser, M A Kroos, R Willemsen, M M Hermans, A M van den Ouweland, J G de Jong, R A Wevers, W O Renier, D Schindler, M J Coll, A Chabas, H Sakuraba, Y Suzuki, and O P van Diggelen. Human alpha-n-acetylgalactosaminidase (alpha-naga) deficiency: new mutations and the paradox between genotype and phenotype. Journal of Medical Genetics, 33(6):458–464, June 1996. URL: http://dx.doi.org/10.1136/jmg.33.6.458, doi:10.1136/jmg.33.6.458. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1136/jmg.33.6.458)

[5. (Bakker2001Human) Henk D Bakker, Marie-Louise CS de Sonnaville, Peter Vreken, Nico GGM Abeling, Johanna EM Groener, Joke LM Keulemans, and Otto P van Diggelen. Human α-n-acetylgalactosaminidase (α-naga) deficiency: no association with neuroaxonal dystrophy? European Journal of Human Genetics, 9(2):91–96, February 2001. URL: http://dx.doi.org/10.1038/sj.ejhg.5200598, doi:10.1038/sj.ejhg.5200598. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.ejhg.5200598)

[6. (Clark2009The) Nathaniel E. Clark and Scott C. Garman. The 1.9 å structure of human α-n-acetylgalactosaminidase: the molecular basis of schindler and kanzaki diseases. Journal of Molecular Biology, 393(2):435–447, October 2009. URL: http://dx.doi.org/10.1016/j.jmb.2009.08.021, doi:10.1016/j.jmb.2009.08.021. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2009.08.021)

[7. (Kanekura2005Three) Takuro Kanekura, Hitoshi Sakuraba, Fumiko Matsuzawa, Seiichi Aikawa, Hirofumi Doi, Yoshio Hirabayashi, Noriko Yoshii, Tomoko Fukushige, and Tamotsu Kanzaki. Three dimensional structural studies of α-n-acetylgalactosaminidase (α-naga) in α-naga deficiency (kanzaki disease): different gene mutations cause peculiar structural changes in α-nagas resulting in different substrate specificities and clinical phenotypes. Journal of Dermatological Science, 37(1):15–20, January 2005. URL: http://dx.doi.org/10.1016/j.jdermsci.2004.09.005, doi:10.1016/j.jdermsci.2004.09.005. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jdermsci.2004.09.005)